TrialEuropean journal of clinical pharmacology2019

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.

Diana L Shuster et al.PubMed ↗Publisher ↗

No numbers read from the abstract.